TY - JOUR AU - Takayama, Shin AU - Namiki, Takao AU - Ito, Takashi AU - Arita, Ryutaro AU - Nakae, Hajime AU - Kobayashi, Seiichi AU - Yoshino, Tetsuhiro AU - Ishigami, Tomoaki AU - Tanaka, Koichiro AU - Kainuma, Mosaburo AU - Nochioka, Kotaro AU - Takagi, Airi AU - Mimura, Masaru AU - Yamaguchi, Takuhiro AU - Ishii, Tadashi PY - 2020 DA - 2020/10/02 TI - A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial JO - Trials SP - 827 VL - 21 IS - 1 AB - We aimed to test our hypothesis that additional administration of traditional Japanese (Kampo) medicine, kakkonto (kakkon-to: KT) and shosaikotokakikyosekko (sho-saiko-to-ka-kikyo-sekko: SSKKS), is more effective in relieving symptoms and preventing the onset of severe infection in mild-to-moderate COVID-19 patients compared to those treated only with conventional treatment. SN - 1745-6215 UR - https://doi.org/10.1186/s13063-020-04746-9 DO - 10.1186/s13063-020-04746-9 ID - Takayama2020 ER -